Vedolizumab as a first-line biologic for Crohn’s?
Trial shows patients with severe disease can achieve remission
About one patient in eight experiences endoscopic remission of Crohn’s disease after completing 26 weeks of treatment with the gut-selective monoclonal antibody vedolizumab, a study shows.
In the phase 3b open-label VERSIFY study, sponsored by Takeda Pharmaceuticals, the biologic was tested in 101 patients with moderately-to-severely active Crohn’s disease.